Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study
To evaluate the effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of roniciclib in cancer patients.

To assess safety and tolerability of roniciclib dosing when administered with and without itraconazole in cancer patients
Medical Oncology
DRUG: Roniciclib (BAY 1000394)|DRUG: Itraconazole (Sporanox)
Maximum observed drug concentration (Cmax) of roniciclib on Cycle 1 Day 1 (without itraconazole), Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 24, 48 and 72 hours after dosing|Area under the concentration vs. time curve from zero to infinity (AUC) of roniciclib on Cycle 1 Day 1 (without itraconazole), Cycle 1 Day 1: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 24, 48 and 72 hours after dosing|Maximum observed drug concentration (Cmax) of roniciclib on Cycle 1 Day 6 (with itraconazole), Cycle 1 Day 6: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, 96 and 120 hours after dosing|Area under the concentration vs. time curve from zero to infinity (AUC) of roniciclib on Cycle 1 Day 6 (with itraconazole), Cycle 1 Day 6: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, 96 and 120 hours after dosing
Collection of Adverse events as a measure of safety and tolerability of roniciclib dosing when administered with and without itraconazole, up to 15 months|Laboratory analyses to assess safety and tolerability of roniciclib dosing when administered with and without itraconazole, Complete blood count, Complete chemistry panel, Coagulation panel, Virology, Urinalysis, Pregnancy test, up to 15 months|Monitoring of vital signs to assess safety and tolerability of roniciclib dosing when administered with and without itraconazole, up to 15 months|East Coast Oncology Group (ECOG) performance status to assess safety and tolerability of roniciclib dosing when administered with and without itraconazole, up to 15 months|Electrocardiogram (12 lead ECG) readings to assess safety and tolerability of roniciclib dosing when administered with and without itraconazole, up to 15 months|Physical examination to assess safety and tolerability of roniciclib dosing when administered with and without itraconazole, up to 15 months|Maximum observed drug concentration (Cmax) of roniciclib after a light meal on Cycle 1 Day -2 (without itraconazole), Cycle 1 Day -2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours after dosing|Area under the concentration vs. time curve from zero to 24 hr (AUC) of roniciclib after a light meal on Cycle 1 Day -2 (without itraconazole), Cycle 1 Day -2: pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours after dosing
To evaluate the effect of itraconazole, a strong CYP3A4 inhibitor, on the pharmacokinetics of roniciclib in cancer patients.

To assess safety and tolerability of roniciclib dosing when administered with and without itraconazole in cancer patients